ClinicalTrials.gg
CompletedNCT01317875Updated Aug 22, 2025Results posted

Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)

A Phase 1 interventional study of Ruxolitinib in Myelofibrosis, sponsored by Incyte Corporation. Completed at 18 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-22.

Sponsored by Incyte Corporation · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
69
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 50 studies testing ruxolitinib in Primary Myelofibrosis — 8 open to participants now, 15 under way, 1 of them phase 3. ruxolitinib · Primary Myelofibrosis.

Enrollment
14th of 50
69 · median 45
Started
2011
with 5 others
Phase 1
12 of 50
2 open now
Registered
5th of 50
by date
Lead sponsor
5 of 50
Incyte Corporation

Among the 50 studies testing ruxolitinib in Primary Myelofibrosis, this one is the 14th largest by enrollment, is one of 6 that started in 2011, is one of 12 in phase 1, and was the 5th registered.

Primary Myelofibrosis

627 studies on the registry are indexed under Primary Myelofibrosis; 125 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

8 of the 50 studies testing ruxolitinib in Primary Myelofibrosis are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About ruxolitinib

ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 101 Primary Myelofibrosis studies recruiting now, 83 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing ruxolitinib in Primary Myelofibrosis, or all of them as a file.
02

Study summary

This is a Phase IB, open-label, dose-finding study of the JAK 1 and 2 inhibitor ruxolitinib in patients with myelofibrosis (MF). The study consists of two periods: the core study period, comprising the dose escalation stage and the safety extension phase up to Week 24, then the extension study period beyond Week 24 and up to 3 years, to further characterize the safety and efficacy of ruxolitinib in this patient population. The dose escalation phase will enroll successive cohorts of patients who receive increasing doses of ruxolitinib until the maximum safe starting dose (MSSD) is determined. In the safety expansion phase, additional patients will be treated with ruxolitinib at the MSSD defined during dose escalation. The primary objective is to establish the MSSD of ruxolitinib in patients with MF and starting platelet counts \< 100 x 10 \^9/L

03

Conditions studied

  • Myelofibrosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Require treatment for MF and classified at least as intermediate risk level 1 defined by the International Working Group.
  • count \< 100x10 \^9/L at screening or at Study Day 1.

Exclusion criteria

Exclusion Criteria:

  • Received transfusion within 14 days prior to Screening evaluations.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
69 participants (actual)

Study arms

  • Experimental
    Stratum -1

    Participants with baseline Platelet counts of 75-99 x10\^9/L

    Drug: Ruxolitinib

  • Experimental
    Stratum -2

    Participants with baseline Platelet counts of 50-74 x10\^9/L

    Drug: Ruxolitinib

Interventions

  • Starting dose of ruxolitinib for cohort 1 in dose escalation phase - 5mg twice a day (BID) Doses will be increased a total of approximately 5mg for successive dosing cohorts based on baseline platelet count

    Also known as: INCB018424

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose Limiting Toxicities

    DLT was defined as the occurrence of any of the following treatment-related toxicities, occurring through Day 28: Any grade ≥ 2 hemorrhagic event ; Any grade thrombocytopenia requiring PLT transfusion; PLT count \< 25x109/L\*; Grade 4 neutropenia (absolute neutrophil count \< 0.5x109/L)\*; Grade ≥ 3 febrile neutropenia\*; Grade ≥ 2 total serum bilirubin with coincident direct bilirubin ≥ 0.5 mg/dL; Grade 3 non-hematologic toxicity for ≥ 7 consecutive days; Grade 4 non-hematologic toxicity. In the dose escalation stage in the core study period, the starting does in both strata was 5mg bid. Successive cohorts of newly enrolled patients received increasing doses of ruxolitinib until the Maximum Safe Starting Dose (MSSD) was determined. Initially, only patients with PLT counts 75-99 x10\^9/L (stratum 1) were allowed to be enrolled. Once safety was established in stratum 1 at the first 2 dose cohorts, eligible population was further expanded to patients with PLT counts 50-74 x10\^9/L (stratum 2).

    Time frame: 28 days

Secondary outcomes

  1. Number of Treatment Emergent Adverse Events (TEAE's)

    Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment.

    Time frame: approximately 4 years

  2. Number of Subjects Achieving ≥ 50% Reduction in Palpable Spleen Length

    Participants achieving ≥ 50% reduction in palpable spleen length relative to study day 1 by treatment and stratum

    Time frame: 24 weeks

  3. Change in Spleen Length as Measure by Palpation Over Time

    Defined as measurement of change in spleen length by palpation from baseline

    Time frame: Day 8, 15, 22, 29, 43, 57, 85, 113, 141, 168, 252, 336, 420, 504, 588, 672, 756, 1008, 1092

  4. PK- C Reactive Protein Levels by PK Quartile (AUC0-12)

    To define the PK and C Reactive Protein relationship using PK Quartiles (AUC 0-12, ng\*h/mL)

    Time frame: 24 weeks

  5. PK- Interleukin 1 Receptor Antagonist Levels by PK Quartile (AUC0-12)

    To define the PK and Interleukin 1 Receptor Antagonist relationship relationship using PK Quartiles (AUC 0-12, ng\*h/mL)

    Time frame: 24 weeks

  6. PK- Tissue Necrosis Factor Receptor 2 Levels by PK Quartile (AUC0-12)

    To define the PK and Tissue Necrosis Factor Receptor 2 relationship using PK Quartiles (AUC 0-12, ng\*h/mL)

    Time frame: 24 weeks

  7. AUC 0-Inf

    Area Under the Serum Concentration Versus Time Curve,Time 0 to Infinity

    Time frame: 0.25 to 0.75, 1 to 3, and 4 to 12 hours postdose on Day 1 and predose, 0.25 to 0.75 hours, and 1 to 3 hours postdose on Day 15, with a random sample on Days 29 and 57

07

Results

Posted Mar 9, 2022

Participant flow

The study was conducted from 03-Mar-2011 to 31-Dec-2019 globally. Participants with MF and baseline PLT of 75 to \< 100 × 109/L are enrolled in Stratum 1;and 50 to \< 75 × 109/L are enrolled in Stratum 2.. The study has a core period (up to week 24) consisting of 2 phases (dose escalation and safety expansion) followed by an extension period (up to 3 years). Participants received increasing doses of ruxolitinib until the Maximum Safe Starting Dose (MSSD) was determined

Participant flow — Overall Study
MilestoneStratum 1 : Cohort 1Stratum 1 : Cohort 2Stratum 1 : Cohort 3Stratum 1 : Cohort 4Stratum 1 : Cohort 5Stratum 2 : Cohort 1Stratum 2 : Cohort 2Stratum 2 : Cohort 3Stratum 2 : Cohort 4Stratum 2 : Cohort 5
Started5320412341800
Completed21112312300
Not completed32929221500
Withdrew: Other0010000000
Withdrew: Noncompliance with study drug0010000000
Withdrew: Progressive disease1020100100
Withdrew: Withdrawal by subject0000100300
Withdrew: Physician decision0110200200
Withdrew: Death0021010400
Withdrew: Adverse event2121512500

Outcome measures

PrimaryNumber of Participants With Dose Limiting Toxicities

DLT was defined as the occurrence of any of the following treatment-related toxicities, occurring through Day 28: Any grade ≥ 2 hemorrhagic event ; Any grade thrombocytopenia requiring PLT transfusion; PLT count \< 25x109/L\*; Grade 4 neutropenia (absolute neutrophil count \< 0.5x109/L)\*; Grade ≥ 3 febrile neutropenia\*; Grade ≥ 2 total serum bilirubin with coincident direct bilirubin ≥ 0.5 mg/dL; Grade 3 non-hematologic toxicity for ≥ 7 consecutive days; Grade 4 non-hematologic toxicity. In the dose escalation stage in the core study period, the starting does in both strata was 5mg bid. Successive cohorts of newly enrolled patients received increasing doses of ruxolitinib until the Maximum Safe Starting Dose (MSSD) was determined. Initially, only patients with PLT counts 75-99 x10\^9/L (stratum 1) were allowed to be enrolled. Once safety was established in stratum 1 at the first 2 dose cohorts, eligible population was further expanded to patients with PLT counts 50-74 x10\^9/L (stratum 2).

Time frame:
28 days
Reported as:
Count of participants · Participants
Number of Participants With Dose Limiting Toxicities
ParticipantsStratum 1 : Cohort 1Stratum 1 : Cohort 2Stratum 1 : Cohort 3Stratum 1 : Cohort 4Stratum 1 : Cohort 5Stratum 2 : Cohort 1Stratum 2 : Cohort 2Stratum 2 : Cohort 3
Number of Participants With Dose Limiting Toxicities00000001
SecondaryNumber of Treatment Emergent Adverse Events (TEAE's)

Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment.

Time frame:
approximately 4 years
Reported as:
Count of participants · Participants
Number of Treatment Emergent Adverse Events (TEAE's)
ParticipantsStratum 1 : Group 1Stratum 1 : Group 2Stratum 1 : Group 3Stratum 2 : Group 1Stratum 2 : Group 2
Number of Treatment Emergent Adverse Events (TEAE's)82016718
SecondaryNumber of Subjects Achieving ≥ 50% Reduction in Palpable Spleen Length

Participants achieving ≥ 50% reduction in palpable spleen length relative to study day 1 by treatment and stratum

Time frame:
24 weeks
Reported as:
Count of participants · Participants
Number of Subjects Achieving ≥ 50% Reduction in Palpable Spleen Length
ParticipantsStratum 1 : Group 1Stratum 1 : Group 2Stratum 1 : Group 3Stratum 2 : Group 1Stratum 2 : Group 2
Number of Subjects Achieving ≥ 50% Reduction in Palpable Spleen Length36413
SecondaryChange in Spleen Length as Measure by Palpation Over Time

Defined as measurement of change in spleen length by palpation from baseline

Time frame:
Day 8, 15, 22, 29, 43, 57, 85, 113, 141, 168, 252, 336, 420, 504, 588, 672, 756, 1008, 1092
Reported as:
Mean · cm
Change in Spleen Length as Measure by Palpation Over Time
cmStratum 1Stratum 2
Day 8-2.8 ± 2.73-3.7 ± 2.98
Day 15-3.3 ± 2.7-5.4 ± 4.4
Day 22-5.2 ± 2.87-5.4 ± 4.81
Day 29-4.4 ± 3.14-6.0 ± 4.23
Day 43-4.6 ± 2.74-5.8 ± 4.31
Day 57-4.5 ± 2.98-5.6 ± 4.52
Day 85-4.5 ± 3.53-5.2 ± 4.32
Day 113-4.7 ± 3.29-6.0 ± 4.74
Day 141-4.9 ± 3.24-6.7 ± 4.43
Day 168-5.2 ± 3.73-5.0 ± 4.78
Day 252-5.5 ± 4.40-3.6 ± 6.67
Day 336-5.1 ± 4.64-5.3 ± 4.86
Day 420-6.1 ± 4.80-4.9 ± 5.75
Day 504-5.7 ± 4.0-4.9 ± 4.91
Day 588-4.7 ± 5.24-5.4 ± 5.61
Day 672-5.8 ± 5.33-4.4 ± 6.60
Day 756-5.7 ± 5.22-6.0 ± 6.03
Day 1008-7.6 ± 3.93-8.0 ± 4.55
Day 1092-6.8 ± 1.71-4.2 ± 5.81
SecondaryPK- C Reactive Protein Levels by PK Quartile (AUC0-12)

To define the PK and C Reactive Protein relationship using PK Quartiles (AUC 0-12, ng\*h/mL)

Time frame:
24 weeks
Reported as:
Mean · micrograms/mL
PK- C Reactive Protein Levels by PK Quartile (AUC0-12)
micrograms/mLStratum 1Stratum 2
Quartile 1 Day 114 ± 5.7312
Quartile 1 Day 2921.2 ± 31.52.6 ± 2.05
Quartile 1 Day 1687.6 ± 85.51 ± 4.98
Quartile 2 Day 19.5 ± 0.7077.7
Quartile 2 Day 2910.2 ± 23.81.84 ± 173
Quartile 2 Day 1688.37 ± 12.82.41 ± 1.45
Quartile 3 Day 16.85 ± 7.286.5
Quartile 3 Day 292.76 ± 4.667.36 ± 9.06
Quartile 3 Day 1687.7 ± 14.94.98 ± 5.1
Quartile 4 Day 10.96 ± 1.055.4
Quartile 4 Day 291.87 ± 1.4312.4 ± 17.8
Quartile 4 Day 1684.88 ± 9.014.9
SecondaryPK- Interleukin 1 Receptor Antagonist Levels by PK Quartile (AUC0-12)

To define the PK and Interleukin 1 Receptor Antagonist relationship relationship using PK Quartiles (AUC 0-12, ng\*h/mL)

Time frame:
24 weeks
Reported as:
Mean · picograms/mL
PK- Interleukin 1 Receptor Antagonist Levels by PK Quartile (AUC0-12)
picograms/mLStratum 1Stratum 2
Quartile 1 Day 1188 ± 116105
Quartile 1 Day 29267 ± 334588 ± 730
Quartile 1 Day 168592 ± 532379 ± 419
Quartile 2 Day 1179 ± 43.1133
Quartile 2 Day 29524 ± 519600 ± 649
Quartile 2 Day 168557 ± 504334 ± 322
Quartile 3 Day 1319 ± 288191
Quartile 3 Day 29304 ± 327452 ± 529
Quartile 3 Day 168549 ± 531960 ± 792
Quartile 4 Day 1120 ± 40.3148
Quartile 4 Day 29604 ± 647475 ± 464
Quartile 4 Day 168562 ± 758378
SecondaryPK- Tissue Necrosis Factor Receptor 2 Levels by PK Quartile (AUC0-12)

To define the PK and Tissue Necrosis Factor Receptor 2 relationship using PK Quartiles (AUC 0-12, ng\*h/mL)

Time frame:
24 weeks
Reported as:
Mean · nanograms/mL
PK- Tissue Necrosis Factor Receptor 2 Levels by PK Quartile (AUC0-12)
nanograms/mLStratum 1Stratum 2
Quartile 1 Day 124 ± 19.86.2
Quartile 1 Day 2920.5 ± 19.725.7 ± 14.4
Quartile 1 Day 16814 ± 4.2422.6 ± 12.6
Quartile 2 Day 113.5 ± 0.7078.2
Quartile 2 Day 2914.9 ± 6.6212.3 ± 7.67
Quartile 2 Day 16836.1 ± 22.918.4 ± 12.6
Quartile 3 Day 121 ± 9.947
Quartile 3 Day 2912.9 ± 4.3213.7 ± 11.6
Quartile 3 Day 16813.3 ± 5.812.4 ± 7.99
Quartile 4 Day 115 ± 4.2424
Quartile 4 Day 2915.7 ± 9.1324.6 ± 17.4
Quartile 4 Day 16814.3 ± 7.6711
SecondaryAUC 0-Inf

Area Under the Serum Concentration Versus Time Curve,Time 0 to Infinity

Time frame:
0.25 to 0.75, 1 to 3, and 4 to 12 hours postdose on Day 1 and predose, 0.25 to 0.75 hours, and 1 to 3 hours postdose on Day 15, with a random sample on Days 29 and 57
Reported as:
Mean · nM*hr
AUC 0-Inf
nM*hr5mg BID10mg BID15 mg BID
AUC 0-Inf1027 ± 3571930 ± 5623756 ± 916

Adverse events

Collected over Up to 4 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Stratum 1 : Cohort 10/5 (0%)2/5 (40%)5/5 (100%)
Stratum 1 : Cohort 20/3 (0%)2/3 (66.7%)3/3 (100%)
Stratum 1 : Cohort 33/20 (15%)10/20 (50%)20/20 (100%)
Stratum 1 : Cohort 41/4 (25%)4/4 (100%)4/4 (100%)
Stratum 1 : Cohort 50/12 (0%)5/12 (41.7%)12/12 (100%)
Stratum 2 : Cohort 11/3 (33.3%)3/3 (100%)3/3 (100%)
Stratum 2 : Cohort 20/4 (0%)3/4 (75%)4/4 (100%)
Stratum 2 : Cohort 34/18 (22.2%)9/18 (50%)18/18 (100%)
Stratum 2 : Cohort 4———
Stratum 2 : Cohort 5———
Most frequent serious events
Showing 10 of 72
Most frequent serious events
EventStratum 1 : Cohort 1Stratum 1 : Cohort 2Stratum 1 : Cohort 3Stratum 1 : Cohort 4Stratum 1 : Cohort 5Stratum 2 : Cohort 1Stratum 2 : Cohort 2Stratum 2 : Cohort 3Stratum 2 : Cohort 4Stratum 2 : Cohort 5
Abdominal painGastrointestinal disorders0/51/30/200/40/12—————
CholelithiasisHepatobiliary disorders0/51/30/200/40/12—————
Gallbladder obstructionHepatobiliary disorders0/51/30/200/40/12—————
Blood bilirubin increasedInvestigations0/51/30/200/40/12—————
Gastric ulcerGastrointestinal disorders—————1/30/40/18——
Multiple organ dysfunction syndromeGeneral disorders—————1/30/41/18——
InfluenzaInfections and infestations—————1/30/41/18——
Splenic ruptureInjury, poisoning and procedural complications—————1/30/40/18——
Sinus node dysfunctionCardiac disorders0/50/30/201/40/12—————
DiarrhoeaGastrointestinal disorders0/50/30/200/41/120/31/40/18——
Most frequent other events
Showing 10 of 227
Most frequent other events
EventStratum 1 : Cohort 1Stratum 1 : Cohort 2Stratum 1 : Cohort 3Stratum 1 : Cohort 4Stratum 1 : Cohort 5Stratum 2 : Cohort 1Stratum 2 : Cohort 2Stratum 2 : Cohort 3Stratum 2 : Cohort 4Stratum 2 : Cohort 5
ThrombocytopeniaBlood and lymphatic system disorders4/52/39/203/411/121/34/414/18——
AnaemiaBlood and lymphatic system disorders3/52/311/202/46/121/33/48/18——
Pain in extremityMusculoskeletal and connective tissue disorders1/50/31/200/43/120/33/43/18——
AstheniaGeneral disorders2/50/33/200/42/122/30/45/18——
PyrexiaGeneral disorders1/50/36/200/42/122/31/44/18——
HyperuricaemiaMetabolism and nutrition disorders0/50/32/200/41/122/30/42/18——
Back painMusculoskeletal and connective tissue disorders0/51/34/200/40/122/31/43/18——
CoughRespiratory, thoracic and mediastinal disorders0/51/32/200/43/122/32/46/18——
EcchymosisSkin and subcutaneous tissue disorders0/52/36/200/40/121/31/42/18——
InsomniaPsychiatric disorders3/50/30/200/41/121/31/41/18——

Baseline characteristics

Full Analysis Set

Age, Continuous
Age, Continuous(years)Stratum 1 : Cohort 1Stratum 1 : Cohort 2Stratum 1 : Cohort 3Stratum 1 : Cohort 4Stratum 1 : Cohort 5Stratum 2 : Cohort 1Stratum 2 : Cohort 2Stratum 2 : Cohort 3Stratum 2 : Cohort 4Stratum 2 : Cohort 5Total
Mean63.00 ± 7.7854.00 ± 4.0063.0 ± 14.7170.4 ± 8.9175.8 ± 3.3067.3 ± 11.0672.5 ± 6.9568.0 ± 11.66——66.4 ± 11.81
Sex: Female, Male
Sex: Female, Male(Participants)Stratum 1 : Cohort 1Stratum 1 : Cohort 2Stratum 1 : Cohort 3Stratum 1 : Cohort 4Stratum 1 : Cohort 5Stratum 2 : Cohort 1Stratum 2 : Cohort 2Stratum 2 : Cohort 3Stratum 2 : Cohort 4Stratum 2 : Cohort 5Total
Female421224237——36
Male118281111——33
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Stratum 1 : Cohort 1Stratum 1 : Cohort 2Stratum 1 : Cohort 3Stratum 1 : Cohort 4Stratum 1 : Cohort 5Stratum 2 : Cohort 1Stratum 2 : Cohort 2Stratum 2 : Cohort 3Stratum 2 : Cohort 4Stratum 2 : Cohort 5Total
Hispanic or Latino00100012——4
Not Hispanic or Latino4215372013——46
Missing11415133——19
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Stratum 1 : Cohort 1Stratum 1 : Cohort 2Stratum 1 : Cohort 3Stratum 1 : Cohort 4Stratum 1 : Cohort 5Stratum 2 : Cohort 1Stratum 2 : Cohort 2Stratum 2 : Cohort 3Stratum 2 : Cohort 4Stratum 2 : Cohort 5Total
White — White5284112316——51
White — Asian011100000——12
White — Other00001001——2
White — Missing00100111——4
ECOG Performance Status
ECOG Performance Status(Participants)Stratum 1 : Cohort 1Stratum 1 : Cohort 2Stratum 1 : Cohort 3Stratum 1 : Cohort 4Stratum 1 : Cohort 5Stratum 2 : Cohort 1Stratum 2 : Cohort 2Stratum 2 : Cohort 3Stratum 2 : Cohort 4Stratum 2 : Cohort 5Total
012916014——24
1319142210——32
210222114——13
08

Study locations

18 sites
  • Winter Park, Florida 32789, United States
  • Baltimore, Maryland 21229, United States
  • Houston, Texas 77030, United States
  • Vienna, Austria
  • Nanjing, Jiangsu, China
  • Chengdu, Sichuan, China
  • Hangzhou, Zhejiang, China
  • Beijing, China
  • Angers, France
  • Paris, France
  • Pierre-Bénite, France
  • Leipzig, Germany
  • Florence, Italy
  • Milan, Italy
  • Terni, Italy
  • Rotterdam, Netherlands
  • Belfast, United Kingdom
  • London, United Kingdom
09

References and documents

Publications

  • Guglielmelli P, Kiladjian JJ, Vannucchi AM, Duan M, Meng H, Pan L, He G, Verstovsek S, Boyer F, Barraco F, Niederwieser D, Pungolino E, Liberati AM, Harrison C, Roussou P, Wroclawska M, Karumanchi D, Sinclair K, Te Boekhorst PAW, Gisslinger H. Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50 x 109/L to <100 x 109/L) at baseline: the final analysis of EXPAND. Ther Adv Hematol. 2022 Sep 10;13:20406207221118429. doi: 10.1177/20406207221118429. eCollection 2022. PubMed 36105914 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2011 to primary completion in Dec 2019, 105 months.

Results were first posted in Mar 2022, 2 years 2 months after primary completion.

Of 68 phase 1 interventional studies under Primary Myelofibrosis, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 103. This study's 105 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2011
First posted
Mar 17, 2011
StartActual
Mar 31, 2011
Primary completionActual
Dec 31, 2019
CompletionActual
Dec 31, 2019
Results first posted
Mar 9, 2022
Last update
Aug 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01317875
Lead sponsor
Incyte Corporation
Collaborators
Novartis
Responsible party
Sponsor
First posted
Mar 17, 2011
Start date
Mar 31, 2011
Primary completion
Dec 31, 2019
Completion
Dec 31, 2019
Results posted
Mar 9, 2022
Last update
Aug 22, 2025

Study contacts

Mark Jones, MD
study director · Incyte Corporation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion